思路迪医药股份(01244)发布公告，思路迪医药于2025年8月20日与楷拓生物订立战略合作框架协议。 思路迪医药目前已建立起拥有全球自主知识产权的mRNA技术平台及LNP递送系统平台。该mRNA技术 平台是基于目前先进的AI技术构建的多模块肿瘤疫苗分析平台(3D-PreciseAg)，可支持海量抗原多组学 分析以及优选肿瘤抗原。同时拥有自主知识产权的AI加强型LNP递送技术平台，可通过AI智能算法对数 千种化合物进行筛选，最终合成多种可覆盖不同递送场景的LNP产品，提升mRNA肿瘤疫苗、in vivo CAR-T/NK免疫细胞治疗等药物的递送效率和靶向性，同时显著降低毒性。 根据该协议，双方将基于思路迪医药的自研具有自有知识产权的AI+mRNA研发平台和脂质体递送系统 (3D-LNP)，与楷拓生物的mRNA规模化生产优势和经验，深化靶向LNP递送(tLNP)、肿瘤疫苗、in vivo CAR-T/NK等领域的合作。具体实施将依据后续正式协议落实。此次合作标志着思路迪医药正不断加速 布局mRNA领域研究，为基于mRNA-LNP技术的创新疗法产品后续临床开发以及未来商业化提供坚实的 产能保障。 ...

Group 1 - The company, Shenlian Biopharmaceutical, announced the successful integration of self-assembling nanoparticle technology with circular mRNA technology to develop the world's first circular mRNA vaccine for swine fever, achieving significant progress [1] - The research results have been published in the internationally recognized immunology journal, "Frontiers in Immunology," indicating the credibility and scientific validation of the findings [1] - The new vaccine is expected to innovate in both antibody persistence and production cost, providing a novel solution for swine fever purification [1] Group 2 - The traditional swine fever E2 subunit vaccine has been crucial in swine fever purification due to its excellent biosafety characteristics and the ability to distinguish between infected and immune animals, but high production costs have limited its widespread application [1] - The company has developed a new generation of swine fever E2 glycoprotein vaccine using a self-built mRNA-LNP technology platform, which combines high immunogenicity with cost-effectiveness [1] - The research team compared different cationic lipid formulations in cmRNA-LNP preparations, finding that the AX4-LNP formulation induced superior cellular and humoral immunity compared to other cationic lipids [1] Group 3 - The study successfully constructed a modular cmRNA-LNP platform integrated with mi3 nanoparticles, overcoming the technical limitations of traditional subunit vaccines and achieving synergistic enhancement of humoral and cellular immunity [2] - This technology not only provides a new generation solution for the development of swine viral vaccines but also has the potential to be expanded to other animal disease vaccines [2]